Trial Profile
A phase III, multi-center, open-label study of methylphenidate transdermal system (MTS) in pediatric patients aged 6-12 with attention-deficit/hyperactivity disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2017
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Shire
- 07 Nov 2006 Status change
- 30 Sep 2006 New trial record.